<b>Pretreatment urinary exosomal ANXA5 and ANXA6 are associated with early non-response and shorter progression-free survival in male patients with small-cell lung cancer receiving first-line platinum-based therapy: a two-stage proteomic study</b>

<p dir="ltr">This dataset contains the source data and analysis code supporting the manuscript "Pre-treatment urinary exosomal ANXA5 and ANXA6 are associated with early non-response and shorter progression-free survival in male patients with small cell lung cancer receiving first-line platinum-based therapy: a two-stage proteomic study".</p><p><br></p><p dir="ltr">Files:</p><p dir="ltr">1) SuppTable_S3_patient_level_anonymized.xlsx - de-identified patient-level data for all 50 patients (anonymized IDs S001-S050): cohort, response group (non-responder SD/PD vs responder CR/PR), age, sex, smoking status, stage, ECOG performance status, NSE, first-line regimen, best response (RECIST v1.1), progression-free survival (months), and urinary exosomal ANXA5/ANXA6 quantitative values (DIA-MS normalized intensities in the discovery cohort; PRM peak areas in the validation cohort).</p><p dir="ltr">2) source_data_all_figures_tables.xlsx - 11 sheets with the values underlying every figure and table: DIA quantification matrix for the seven ANXA family proteins (Fig. 3A/3C), differential-expression and FDR results, ROC coordinates and AUC/DeLong summaries (Fig. 5, Table 2), decision-curve and calibration values (Fig. 6), per-patient survival data and high/low group assignment (Fig. 7), Cox model estimates (Fig. 8, Table 4), subgroup analyses and recomputed baseline comparisons (Table 1).</p><p dir="ltr">3) analysis scripts (step1_verify.py, step2_stats.py, step3_survival.py, step4_figures.py, build_deposit_workbook.py) - Python scripts reproducing all statistics and figures.</p><p dir="ltr">4) README.txt - description of every file and notes on reproducibility.</p><p><br></p><p dir="ltr">No data points were extracted from images for analysis.

Patient identifiers were removed before sharing; raw clinical records containing identifiable information cannot be made publicly available under the terms of the institutional ethics approval (Beijing Shijitan Hospital, No. 5, 2017) and participant informed consent.</p><p><br></p><p dir="ltr">These analyses are a secondary analysis of a urinary exosomal proteomics dataset generated in the same experimental batch as the previously published RAB11A study (Wang W, et al. Clin Proteomics 2025; doi:10.1186/s12014-025-09554-4).